Qiagen (NYSE:QGEN – Get Free Report) will be announcing its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of $0.54 per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.
Qiagen (NYSE:QGEN – Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.03. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The business had revenue of $496.00 million for the quarter, compared to the consensus estimate of $495.45 million. During the same period last year, the firm earned $0.53 earnings per share. The company’s quarterly revenue was down .2% on a year-over-year basis. On average, analysts expect Qiagen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Qiagen Trading Up 0.1 %
Shares of QGEN stock opened at $41.83 on Wednesday. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.77 and a quick ratio of 1.46. The company has a market cap of $9.55 billion, a price-to-earnings ratio of 28.07, a PEG ratio of 3.17 and a beta of 0.39. Qiagen has a 1 year low of $34.74 and a 1 year high of $47.44. The firm has a fifty day moving average price of $44.58 and a 200-day moving average price of $43.56.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on QGEN
About Qiagen
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
Recommended Stories
- Five stocks we like better than Qiagen
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- Why is the Ex-Dividend Date Significant to Investors?
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- Technology Stocks Explained: Here’s What to Know About Tech
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.